Fluvoxamine for the treatment of COVID-19.

Marzolini, Catia; Marra, Fiona; Boyle, Alison; Khoo, Saye; Back, David J

Marzolini, Catia; Marra, Fiona; Boyle, Alison; Khoo, Saye; Back, David J.

Marzolini C; Division of Infectious Diseases & Hospital Epidemiology, University Hospital Basel and University of Basel, Basel, Switzerland. Electronic address: catia.marzolini@usb.ch.
Marra F; Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK; Department of Pharmacy, NHS Greater Glasgow and Clyde, Glasgow, UK.
Boyle A; Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK; Department of Pharmacy, NHS Greater Glasgow and Clyde, Glasgow, UK.
Khoo S; Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
Back DJ; Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.

Lancet Glob Health ; 10(3): e331, 2022 03.

Article in English | MEDLINE | ID: covidwho-1683796

Subject(s)

COVID-19 Drug Treatment; Fluvoxamine; Fluvoxamine/therapeutic use; Humans; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Fluvoxamine / COVID-19 Drug Treatment Limits: Humans Language: English Journal: Lancet Glob Health Year: 2022 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google